Pharmacokinetics in Drug Discovery: Review of Basic Pharmacokinetic Concepts
Pharmacokinetics in Drug Discovery: Review of Basic Pharmacokinetic Concepts
Pharmacokinetics in Drug Discovery: Review of Basic Pharmacokinetic Concepts
ABSTRACT: The aim of this current review is to summarize the present status of
pharmacokinetics in Drug Discovery. The review is structured into four sections. The
first section is a general overview of what we understand by pharmacokinetics and the
different LADMET aspects: Liberation, Absorption, Distribution, Metabolism, Excre-
tion, and Toxicity. The second section highlights the different computational or in silico
approaches to estimate/predict one or several aspects of the pharmacokinetic profile of
a discovery lead compound. The third section discusses the most commonly used
in vitro methodologies. The fourth and last section examines the various approaches
employed towards the pharmacokinetic assessment of discovery molecules; including all
the LADME processes, discussing the different mathematical methodologies available
to establish the PK profile of a test compound; what the main differences are and
what should be the criteria for using one or another mathematical approach. The
major conclusion of this review is that the use of the appropriate preclinical assays
has a key role in the long-term viability of a pharmaceutical company since applying
the right tools early in discovery will play a key role in determining the company’s
ability to discover novel safe and effective therapeutics to patients as quickly as
possible. ß 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci
97:654–690, 2008
Keywords: absorption; toxicology; structure–activity relatioship (SAR); population
pharmacokinetics; pharmacokinetic/pharmacodynamic models; computational ADME;
biophysical models; biopharmaceutics classification system (BCS); bioequivalence;
ADME
chemical structure. Restated, when any biotrans- solutions. . .etc) determines the disposition of the
formation of the parent compound takes place and drug.8–12 Response and toxic effects are the other
even if the resulting metabolites remain in the two key aspects to consider since they are the
body, it has been eliminated. main reasons for Drug Discovery failure (see
Fig. 1). In summary, when we refer to the different
individual assays that should be performed to
LADMET-R and Pharmacokinetics characterize the PK profile of a new drug in vitro,
When the studies are focused solely in one specific in situ, in vivo, or in silico we should also consider,
pharmacokinetic aspect (Absorption, Distribu- besides the ‘‘gold standard’’ ADME, (1) release
tion, Metabolism, or Excretion) by in vitro, from the pharmaceutical form, (2) toxicity, and (3)
in situ, in vivo, or in silico techniques it is usually activity/response in the target site (LADMET-R).
referred to as ADME studies whereas the name
Pharmacokinetics is normally reserved to in vivo
studies where an integrated approach of all DISCOVERY AND DEVELOPMENT
the ADME processes together is taken. For
either ADME or Pharmacokinetics, the truth of New drug development can be divided in two
the matter is that under both approaches, it is different stages: discovery and development.
necessary to command a more or less sophisti- Recently, Kola and Landis13 reviewed the major
cated knowledge of algebra and calculus to causes of attrition in development (see Fig. 1). In
correctly interpret the dataset. Although ADME their review, they showed how the root causes of
assays have been the gold standards in PK, there drug failure have evolved over time (1991–2000).
are additional tests that should be incorporated, In 1991, PK and bioavailability were the major
since they play a key role in Drug Discovery and reasons for drug failure (40%) dropping dramati-
further development. Liberation of the drug from cally to 10% in 2000. This significant change is
the pharmaceutical form is a key parameter in mainly due to the time and effort that Industry
bioequivalence studies (e.g., a sustained release has invested in the last decade toward a deeper
versus immediate release formulation)2–7 or, for and better understanding of PK, partially in an
intravenous formulations, where the rate of attempt to overcome poor bioavailability but also
release from the formulation (liposomes, micellar trying to look into more predictive kinetic
Figure 1. Main reasons for drug development failure. Adapted from Kola 200013 and
Tufts Center for the Study of drug Development.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
656 RUIZ-GARCIA ET AL.
behavior of the drug candidates to allow for more the sponsor. The project team needs to be aware of
efficient dose regimens. Lack of efficacy and safety the target product profile in order to make
were reported as the most relevant causes of why educated decisions about the direction that the
compounds undergo attrition in the clinic in 2000 project needs to evolve in order to reach the next
(30%). The Tufts Center for the Study of Drug milestone in development. Components of the
Development14 published in 2005 the three main target product profile are: disease indication,
reasons for terminating unpromising new drugs. minimum efficacy requirements, required safety
Again, safety and efficacy were listed among the profile, desirable dose regimen, dosage form,
main three. In summary, the identified issues in maximum cost of goods, planned date of regula-
that report have been the main focus of study in tory submission and expected approval date.18
recent years as well as a driving force determining In summary, when planning exploratory stu-
which strategy to follow in Drug Discovery. The dies in humans, under an Investigational New
composite of activity, safety, and acceptable Drug (IND) application, there is some preclinical
LADME properties, rather than a specific attri- data as well as chemistry, manufacturing and
bute, will dictate the success of the drug program. controls information that need to be generated.
In order to identify potential liabilities in dis- The approaches taken in generating this data can
covery and eliminate those molecules from further be optimized expediting the progress into devel-
consideration, high throughput screening (HTS) opment and increasing the chances of success of
of reliable and appropriate in vitro, and/or in situ the IND filing by compiling a good quality dataset
assays seem to be the fastest and more efficient in an efficient manner. Depending on the goals of
way to proceed,15–17 as shown in Figure 2. the proposed investigation, the amount of data
Generally, when a drug is granted to progress that need to be submitted can vary.19
into development, a project team is formed
with members of different areas of expertise
(i.e., including, but not restricted to, toxicology, DRUG DISCOVERY:
pharmacokinetics, clinical development, medic- HOW DOES THIS WORK?
inal chemistry, formulation, marketing and reg-
ulatory affairs), with the goal of establishing an The quality and quantity of preclinical data
early development plan. Successful drug develop- provided by discovery groups to support the
ment is a result of getting to this stage with development of a new drug has considerably
enough information about the previously men- improved in the last few years. This is due to the
tioned processes (LADMET-R) in conjunction with acknowledgement from Industry of the relevance
a worthwhile investment that provides value to of this information to the success of the drug as
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 657
mentioned above. A variety of in vitro assays have (high permeability, low solubility, HP:LS), class 3
been automated through the use of robotics. (low permeability, high solubility, LP:HS), and
In silico models are being used to assist in the class 4 (low permeability, low solubility, LP:LS),
selection of the right assay and the set of see Figure 3.
compounds undergoing further in vitro screening. This analysis points out conditions under which
With the emerging new computational models no in vitro–in vivo correlation may be expected for
(in silico), a deeper understanding of the relation- example, rapidly dissolving low permeability
ship between important LADME-T parameters drugs. Furthermore, it is suggested that for very
and molecular descriptors and/or in vitro para- rapidly dissolving high solubility drugs, for
meters has been achieved, allowing for an early example, 85% dissolution in less than 15 min, a
estimation of several LADME-T properties (see simple one-point dissolution test is all that may be
Tab. 1). needed to insure bioavailability. For slowly
HTS facilitates a researcher to effectively dissolving drugs, a dissolution profile is required
conduct some biological test to a large number with multiple time points in systems which would
of potential therapeutic moieties.20 Through this include low pH, physiological pH, and surfactants,
process, rapid discrimination of active ingredients where the in vitro conditions should mimic the
versus undesirable compounds based on the in vivo processes. The draft guidance document
results of the particular assay can be achieved. entitled ‘‘Waiver of In Vivo Bioavailability and
The main difference of this strategy versus the Bioequivalence Studies for Immediate Release
traditional pharmaceutical screening is that Solid Oral Dosage Forms Containing Certain
less rigorous results are needed. There are few Active Moieties/Active Ingredients Based on a
samples from many compounds as opposed to a Biopharmaceutics Classification System’’ pro-
very rich database from few compounds. HTS poses to further expand the regulatory applica-
screening is, in essence, a single goal to which all tions of BCS and also recommends methods for
the data may subsequently be applied. HTS is classifying drugs and immediate release formula-
used at early stages of discovery to gather tions.25 However, Wu and Benet26 suggest an
LADME-T information that serve as key factors alternative classification attending to solubility
for candidate selection. As a result, there has been values and metabolism rather than permeability
a recent focus on enhancing the efficiency of values, The Biopharmaceutics Drug Disposition
obtaining absorption, disposition, and toxicity Classification System (BDDCS). The authors,
data, which has permitted LADME-T scientists while recognizing that drug metabolism can differ
to contribute more effectively to the drug depending on the drug’s solubility and perme-
discovery process. ability characteristics, consider that switching
Since the oral route is the preferred adminis- permeability values to extent of elimination would
tration route for patients, and this fact assures be less restrictive, expanding the Class I drugs
compliance of the drug therapy, a lot of time and eligible for waiver of bioequivalence (BE).27
effort has been invested toward a good under- For drugs with low permeability, the rate at
standing of the physicochemical properties that which they are being actively carried through
play a key role in bioavailability. Bioavailability the GI and reaching the systemic circulation is
has been defined by the FDA as the rate and extent highly dependent on the carrier-mediated sys-
to which the active ingredient or active moiety is tems involved. Both influx and efflux under these
absorbed from a drug product and becomes circumstances will play an active role in the oral
available at the site of action.21 Thus, for oral bioavailability of the compound. In light of
pharmaceutical forms, systemic exposure is going this, Klopman et al.28 discussed the importance
to be highly dependent on the extent of absorption of lipophilicity in membrane transport models.
in the gastrointestinal tract (GI). The Biophar- Several experimental techniques have been
maceutics Classification System (BCS)22 as a described to evaluate intestinal absorption
drug development tool allows for the estimation including physicochemical measurements (e.g.,
of contributions of the three major factors that solubility, lipophilicity, partition coefficients),
affect drug absorption: dissolution, solubility, and subcellular fractions (brush border membrane
intestinal permeability.22–24 Based on in vitro vesicles, basolateral membrane vesicles), cell
solubility and in vivo permeability values, drugs culture-based models, artificial membranes, iso-
can be divided into four groups: class 1 (high lated tissues, and organ preparations. These
permeability, high solubility, HP:HS), class 2 techniques are briefly described in this review
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
658
RUIZ-GARCIA ET AL.
Descriptor
Involved/Substrate Used Modeling Approach Comments Reference
Elimination CYP1A2 Pharmacophore 73
DOI 10.1002/jps
Absorption Partition coefficient Biophysical models Absorption/permeability 246,124
and Molecular Weight predictions
PATQSAR 100
QSAR 28
DOI 10.1002/jps
Liposome partitioning Correlation 128
Polar surface data Correlation 142,247
Polar surface data Correlation Solubility predictions 142
Molecular descriptors ANN 101,103
Aminoacid sequence SVM 248
Everted intestinal rings Correlation Drug accumulation predictions 139
Partition coefficient, Molecular weight Biophysical models Bioavailability Predictions 249
In situ absorption rate constant values 249,250
(Rat small intestine)
Physico-chemical properties (HDM, Non linear regression 142
Caco-2 and 2/4/A1)
Liberation In vitro dissolution test IVIVC Bioavailability predictions 2–7,105,106
Physicochemical and structural factors QSAR/ORMUCS 29
Response Partition coefficient, Molecular weight PATQSAR In vitro evaluation for prediction 100
of in vivo response
Atom typing Naive Bayes classifier 25
Physicochemical descriptors 2D-QSAR 64
Toxicity Chemical structure (Ames test) Correlation In vitro evaluation for prediction 43
of toxic effects in vivo
Identification of potential hERG channel Neuronal Networks and 17
blockers (Dofetidine DisplacementTest) Bayesian statistics
Subcutaneous and ocular toxicity (MTT) Correlation 55,57
34
Adapted from de Groot and Ekins.80,251.
PHARMACOKINETICS IN DRUG DISCOVERY
659
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
DOI 10.1002/jps
Table 2. In Vitro Systems for Permeability and Protein Binding Studies
drug protein binding in plasma, with the two that the in vitro systems respond as the in vivo
predominant methods being ultrafiltration (UF) tissue would. In vitro studies should be conducted
and equilibrium dialysis (ED).36,37 with concentrations and exposure times similar to
There is a clear need for companies to find ways the in vivo conditions. The in vitro models may
to evaluate safety of drug candidates earlier in the allow high throughput screening, decreasing the
development process. Animal toxicology studies number of chemicals tested in whole animals.
are the foundation of an IND. The principal Mutagenicity screening is a regulatory require-
safety concerns are usually in the area of genetic ment for drug approval since they imply a toxic
toxicology, target organ toxicity and cardio- risk in humans.38 The International Agency
safety. The identification of HTS assays that for Research on Cancer (IARC) discussed in a
can accelerate the advance of the drug candidate consensus report39 the term ‘‘genotoxicity,’’ con-
into more relevant in vivo testing as soon as sidering that this term includes both direct and
possible is the main goal in the discovery stages. indirect effects in DNA. Direct effects are con-
There are several toxicity studies that are sidered inductions of mutations (gene, chromo-
routinely performed depending on the nature of somal, genomial, and recombinational) that at the
the drug. Genotoxicity, cytotoxicity, and target molecular level are similar to events known to be
organ toxicity may be, at least in a first instance, involved in carcinogenesis. Indirect DNA effects
evaluated through in vitro screening. The use of involve surrogate events associated with muta-
positive (known toxic reagents) and negative genesis (e.g., unscheduled DNA synthesis (UDS)
controls (non toxic reagents) is necessary to assure and sister chromatid exchange (SCE), or DNA
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
Table 4. Online Information and Software Resources for Absorption as Well as Other LADME Aspects
DOI 10.1002/jps
cerius2/ aqueous solubility, human CYP 2d6, blood–brain barrier penetration, serum protein
cerius2products/c2adme.html binding, and human hepatotoxicity.
http://www.compudrug.com/ Since the early 1960s, lipophilicity has proven to be very important molecular description, Pallas
often well-correlated with the bioactivity of chemical entities. Lipophilicity and hydrophobicity
are measured by lipophilic and hydrophobic indices, such as the logarithm of a partition
coefficient, which reflects the equilibrium partitioning of a molecule between a nonpolar and
polar (aqueous) phase. A new artificial neural network using atomic fragmental descriptors
has been developed to predict the octanol-water partition coefficient (logP). The fragmental
descriptors were obtained from the Atomic2005 linear logP calculation method implemented in
Pallas PrologP program. Using a numerically optimized weighted average of the older methods
and the current one, the result is significantly more accurate than the previous method, and
provides an exceedingly accurate prediction. The new logP prediction method was implemented
into the Pallas 3.4 version.
http://www.simulations-plus.com/ In an effort to help pharmaceutical companies bring new drugs to market faster and for less cost, Gastro-Plus
products.html Simulations Plus has developed GastroPlusTM, a unique software program that simulates the
dissolution and absorption of a drug in the human gastrointestinal tract.
http://www.simulations-plus.com/ ADMET Predictor is an advanced computer program that enables pharmaceutical researchers to ADMET
products.html estimate ADME properties (such as permeability, solubility, lipophilicity, diffusivity, etc.) of new Predictor
chemical entities (NCE’s) from their molecular structure.
http://www.simulations-plus.com/ (Dose Disintegration and Dissolution) is a new tool for forulation scientists that simulates DDDPlus
products.html the in vitro disintegration and dissolution of dosage forms in USP Paddle, Basket, and
Flow-Through experiments.
http://www.pasteur.fr/recherche/unites/ Database describing the properties and the protein composition of experimentally investigated ABCISSE
pmtg/abc/database.iphtml ATP-binding cassette (ABC) systems. In addition, we report complete inventories of the
predicted ABC systems for organisms whose complete genome sequence is known. In the
latter case, ABC proteins and their interacting partners were identified by comparing the
proteomes of these organisms to the full content of ABCISSE. Systems were reconstructed and
sorted in families and subfamilies according to the phylogenetic and functional classification,
which was described in our publications. We predict the polarity of transport, the substrate
specificity, and the biological role of these systems.
http://133.9.194.61/tp-search/index.html TP-Search is a comprehensive database on drug transporters, which are thought to play an TP-Search
important role in the pharmacokinetics of drugs. All the infomation is extracted from a large
number of published papers. With this database, users can obtain various kinds of basic
information on drug transporters.
http://nutrigene.4t.com/humanabc.htm Human ATP-binding cassette transporters
PHARMACOKINETICS IN DRUG DISCOVERY
(Continued)
663
genefamily/abc.html
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
Table 5. Online Information and Software Resources Mainly Focused in Metabolism
DOI 10.1002/jps
URL Description Name
http://drnelson.utmem.edu/ Cytochrome P450 Homepage
CytochromeP450.html
http://www.cypalleles.ki.se/ Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee
http://www.icgeb.org/p450srv/ The goal of this www Directory is to facilitate access to electronic resources
world-wide for all researchers working in the field of P450 proteins and
P450-containing systems.
http://medicine.iupui.edu/flockhart/ Cytochrome P450 drug interactions table
P450 inhibiting drugs
http://www.accelrys.com/products/cerius2/ This is a package of six predictive ADME/Tox models—human intestinal absorption, C2 adme
cerius2products/c2adme.html aqueous solubility, human CYP 2D6, blood–brain-barrier penetration, serum protein
binding, and human hepatotoxicity
http://www.accelrys.com/products/chem_ This database has been compiled from and based on two noteworthy journals of the Metabolism
databases/databases/metabolism.html Royal Society of Chemistry (RSC): ’Biotransformations’ and ’Metabolic Pathways of
Agrochemicals’. It covers the metabolic pathways of drugs, agrochemicals and industrial
chemicals in various species. On this strong foundation, new entries are added based
on the expert abstraction of pertinent and relevant literature references
http://www.compudrug.com/ The knowledge base of the MetabolExpert module of Pallas has been extended with new MetabolExpert
metabolic reactions. The extension includes a set of special metabolic reactions collected
from the scientific literature focusing on the metabolisms of toxic and drug-like organic
compounds. Thanks to the inserted reactions, the new version of MetabolExpert will
manage a series of special metabolisms, including ring opening and closing reactions
http://www.lhasalimited.org/ Meteor is a computer program that helps scientists who need information about the METEOR
index.php?cat¼2& sub_cat¼68 metabolic fate of chemicals and want to be more efficient, more effective and make
better decisions. The program uses expert knowledge rules in metabolism to predict
the metabolic fate of chemicals and the predictions are presented in metabolic trees.
The only information needed by the program to make its prediction is the molecular
structure of the chemical
http://multicase.com/products/products.htm An expert system capable, when coupled with appropriate dictionaries, to predict the META
metabolic transformations that may be produced when the molecules are ingested
or dumped in the environment. The program is totally interfaced with MCASE
and permits a complete evaluation of the potential toxicological effect of a
molecule and its metabolites
http://mhc.com/Cytochromes/ P450, UGT, and P-gp drug interactions
PHARMACOKINETICS IN DRUG DISCOVERY
665
DOI 10.1002/jps
DOI 10.1002/jps
Table 7. In Silico Online information and Databases
potential. Abnormalities in this channel may lead leads and the elimination of unsuitable ones.
to either Long QT syndrome (LQT2) (with loss of Although these models can never be accurate
function mutations) or Short QT syndrome (with enough to replace real circumstances, many of
gain of function mutations). Both are potentially them can be extremely useful if they are built
fatal cardiac arrhythmia due to repolarization under the correct assumptions and right set of
disturbances of the cardiac action potential. data. When the in silico models have been
Erroneous drug binding to this channel may lead carefully developed and rigorously validated the
to acquired Long QT Syndrome.63 information they provide can be valuable in early
In silico models, described below, are also being Drug Discovery. It is, therefore, not surprising
used for predicting activity as well as toxicity15. that there is considerable interest in developing
Klopman et al.25 have developed a model for MDR mathematical models capable of accurately pre-
reversal agents (to overcome Multi-Drug Resis- dicting some LADME-T key information for new
tance) to estimate the MDR reversal activity of drug candidates. However, the misleading use
compounds. The same author discussed the and interpretation of in silico LADMET is often
importance of lipophilicity values (represented the reason why these models have been exten-
as the logarithm of the n-octanol/water partition sively criticized by a large part of the scientific
coefficient) and its correlation with their pharma- community.65 These models are usually based in
cological and toxic activities.29 Kazius et al.43 were in vitro data and/or physico-chemical properties.
able to perform mutagenicity predictions of an Two different types of computational models are
independent validation set of 535 compounds with being used currently: molecular and data model-
an error percentage of 15%. The authors con- ing. A brief description of the fundaments of the
cluded that toxic properties can often be related to most used computational models is presented
substructures, which are generally identified as below and listed in Table 1.
toxicophores, and that these toxicophores can be
applied to risk assessment processes and can
guide the design of chemical libraries for hit and Molecular Modeling
lead optimization. Yoshida et al. have used
The main objective of molecular modeling is to
some physicochemical descriptors (n-octanol/
assess the potential interaction between the
water partition coefficient, topological polar sur-
studied drug and proteins involved in LADMET
face area, diameter, summed surface area of
processes (e.g., carrier-mediated systems such us
atoms with partial charges) to carry out 2D-
p-gp, enzymes responsible of either phase I (e.g.,
quantitative structure–activity relationship (2D-
CYPs) or II biotransformation(e.g., Glutathione
QSAR) studies on 104 hERG channel blockers
tranferases). Under molecular modelling, we can
with diverse structures collected from the litera-
distinguish: Ligand-based models, Structure-
ture, thus formulating interpretable models to
based models, and Homology Models.
guide chemical-modification studies and virtual
screening.64 Combination of predictive models has
Ligand-Based Models
also been performed with great success. O’Brian
et al. combined hERG channel blocking and These attempts to link chemical structures with
CYP450 2D6 inhibition computational models observed activities based on information about
with better predicted values than their individual active site, shape, electronic properties and con-
predictions.17 formation of substrates, inhibitors or metabolic
products. The simplest one is QSAR: Quantitative
Structure–Activity relationship. Three-dimensional
IN SILICO LADMET quantitative Structure–Activity relationship (3D-
QSAR) refers to the analysis of the quantitative
The line between in silico LADME-T and in vitro- relationship between the biological activity of a set
in silico LADME-T is difficult to define since the of compounds and their spatial properties using
majority of the in silico models use not only statistical methods.66–69 3D-QSAR are often based
physicochemical parameters but also some in vitro on Molecular Field Analysis, MFA. MFA employs a
data (see Tab. 1). combination of reasonable molecular description,
In recent years, the number of computational statistical analysis, and graphical display of
models for the different LADMET processes has results.67,70,71 Molecular structures are described
considerably increased with the aim of promising with molecular interaction energies as steric and
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 669
electrostatic fields surrounding the molecules; the ANN may include molecular modeling and data
statistics is computed by partial least square (PLS) modeling.101–103
regression analysis and the output is displayed as Li et al.104 have done excellent work describing
contours superimposed on the molecules. The the most recent explored statistical learning
comparative MFA, (CoMFA) methodology assumes approaches such as neural networks (NN), sup-
that a suitable sampling of steric and electrostatic port vector machines (SVM), etc. The authors
fields around a set of aligned molecules provides all concluded that both classification-based and
the information necessary for understanding their regression-based statistical learning methods
biological properties.72 If no structural information have consistently shown promising capability
is available, an alternative means to assess for predicting chemical agents of diverse ranges
potential interactions is to use pharmacophore of structures and of a wide variety of LADMET
models. These are ligand-based models where poperties.
different structures of ligands or their properties Table 1 contains a list of references of published
overlay in 3D space in an attempt to describe the in silico work in LADME-T.
physical, spatial, and chemical properties of the
active site.10,73–82
In Vitro In Vivo Correlations (IVIVC)
Structure-Based Models
Bioequivalent products are those whose rate and
Included in this category are X-ray crystallogra- extent of absorption do not show significant
phy,83 nuclear magnetic resonance (NMR),84 differences when administered at the same dose.21
spectroscopy and electron microscopy. These The bioequivalence of two drug products is usually
models determine the 3D structure of proteins evaluated through in vivo assays in human
through a variety of means. However, it is often volunteers. However, under some particular
very difficult to use these techniques due to the conditions, it should not be necessary to carry
nature of the proteins (e.g., difficult to crystallize, out an in vivo pharmacokinetic study to assure
poor solubility, large molecular size). bioequivalence; a well validated in vitro study
should be able to assess that. From an ethical
point of view, if the assay with human volunteers
Homology Models
is not essential to demonstrate the equivalence
As a result of the difficulties mentioned above between two formulations, the assay should not be
when trying to elucidate the 3D structure of performed, but, on the other hand, we need to
proteins, these models were developed. Homology assure that the in vitro surrogate is reliable. The
models are an alternative method to elucidate the factors that we have to analyze to establish the
3D structure of proteins. These models are based theoretical basis for correlating in vitro dissolu-
on the fact that the 3D structure of a protein is tion and in vivo absorption are the parameters
related to its amino acid sequence since proteins that control rate and extent of absorption. The
with similar amino acid sequence tend to adopt basic concept is if two drug products containing
similar 3D structure.85–90 the same drug have the same concentration time
profiles at the intestinal membrane surface, then
they will have the same rate and extent of
absorption. Two conditions are necessary for this
Data Modeling
statement to be true: the two drug products have
Data modeling uses statistical tools to search the same in vivo dissolution profile under all
for correlations between a given property and a luminal conditions and none of the formulation
set of physicochemical descriptors. Quantitative components affects the membrane permeability or
structure–activity relationship (QSAR),28,29,64,91–95 intestinal transit time.
quantitative structure–property relationship IVIVC has been defined by the Food and
(QSPR),96–99 population Analysis by topology- Drug Administration (FDA) as a ‘‘predictive
based QSAR (PATQSAR)100 and Artificial Neural mathematical model describing the relationship
Networks (ANN) are some examples of data between an in vitro property of a dosage form and
modeling. ANN is an adaptive system that chang- an in vivo response’’.21,27 Generally, the in vitro
es its structure based on external or internal property is the rate or extent of drug dissolution or
information that flows through the network. release while the in vivo response is the plasma
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
670 RUIZ-GARCIA ET AL.
drug concentration or amount of drug absorbed. specific biomarker identification for various pur-
The main objective of developing and evaluating poses ranging from disease monitoring to disease
an IVIVC is to establish the dissolution test as a progression and prognosis.
surrogate for human bioequivalence studies,
which may reduce the number of bioequivalence
studies performed during the initial approval Proteomics
process as well as with certain scale-up and post Proteomics is a high throughput study of proteins,
approval changes.105,106 Two step or one step particularly their structures and functions. Pro-
methods can be applied to obtain these correla- teomics is much more complicated than genomics.
tions. Using the two-step method, by deconvolu- Most importantly, while the genome is a rather
tion or by a mass balance method, the in vivo constant entity, the proteome differs from cell to
function is computed and from dissolution assays, cell and is constantly changing through its
the in vitro variable is calculated, then, in a second biochemical interactions with the genome and
step, plasma concentration are predicted by the environment. The entirety of proteins in
convolution based on the in vitro data. A one step existence in an organism throughout its life cycle,
method involves a convolution step where plasma or on a smaller scale the entirety of proteins found
concentrations predicted from the model and in a particular cell type under a particular type of
those observed are directly compared. Published stimulation, are referred to as the proteome of
work in this matter has been referenced in the organism or cell type respectively.110–112 Since
Table 1. proteins play a central role in the life of an
organism, proteomics is instrumental in the
discovery of biomarkers, such as markers that
Genomics, Proteomics, and Metabonomics indicate a particular disease.113–117
Lately, these terms have been incorporated into
many scientists vocabulary with not always a Metabonomics
clear idea of the intended meaning.
Metabonomics has been defined as the quantita-
In addition to the traditional information about
tive measurement and identification of the
the disease state, we now posses a set of new
biochemicals contained in a biological sample
descriptors obtained by molecular profiling. In
such as the metabolic response of living systems to
other words, we have access to large scale of
pathophysiological stimuli or genetic modifica-
systematic readouts at various levels such as DNA
tion. This approach has been used in toxicology,
content (genomics), protein expression (proteo-
disease diagnosis, and a number of other fields.
mics), and measurements of metabolites (meta-
This technology has been used to identify bio-
bonomics). Hopefully, the combination of these
markers for disease as well as to identify off-target
different readouts will provide us a combination of
side effects in marketed drugs and new chemical
potential biomarkers as well as better predictors
entities in development.15,60,118–120
of a disease state.
A similar and related concept that is worth
defining here is Metabolomics, which refers to the
Genomics
study of the chemical fingerprints that specific
Genomics is the study of an organism’s genome cellular processes may produce. The study of
and the identification of the genes involved in metabolite profiles will fall into this category.
biological processes. Genomics has the potential of Although there is still no absolute agreement,
offering new therapeutic methods for the treat- there is a growing consensus that the difference
ment of some diseases, as well as new diagnostic between the two terms resides in the fact that
methods. As a consequence of the identification of ‘‘metabolomics’’ places a greater emphasis on
genome sequences, it is possible to engineer DNA comprehensive metabolic profiling, while ‘‘meta-
microarrays, which can measure gene expression bonomics’’ is used to describe multiple (but not
of thousands of genes simultaneously.60,107,108 necessarily comprehensive) metabolic changes
New applications in the field of genomics are caused by a biological perturbation.
emerging in two major areas.109 The first one The integration of genomic, proteomic and
focuses on understanding the mechanism of action metabonomic data constitutes a very powerful
involved in disease states or compound-induced data source for in silico analysis. Although we do
phenotypic changes. The second one involves not fully understand the complexity of the
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 671
biological systems and pathologies, by gathering of the solute from the aqueous phase indicates
the various sources of information and analyzing how much solute travelled to the organic phase.
the data together, we will certainly see increas- Both phases, aqueous and organic, should be
ed contributions toward the establishment of saturated in each other to avoid changes in
fingerprints for toxicity, metabolism and other volume when they contact as that will introduce
LADMET-related processes. considerable error in the determination of this
parameter. The partition coefficient is defined as
the concentration ratio between the organic and
IN VITRO LADMET
aqueous phase as follows:
The following in vitro assays are probably the Co ðQai Qaf Þ=Vo
most common screening tools for the PK aspects P¼ ¼
Ca Qaf =Va
already commented on throughout this review.
Tables 2 and 3 list these in vitro assays pointing
Where Qai and Qaf represent the amount of
out the parameter assayed and some relevant
solute in the aqueous phase before and after
published work in that matter.
being in contact for a specific period of time
with the organic phase in continuous agitation.
Dissolution Studies The pH value of the aqueous phase along with
the temperature used for the partitioning are
Dissolution studies are routinely performed as a the variables that determine the value of this
part of the quality protocol of solid dosage forms, parameter.
because these studies help to ensure that the
manufacturing process has not deviated signifi- Liposomes
cantly from the established standards. The use of
dissolution assays as a quality control index Liposomes are lipid bilayer vesicles used as
requires a simple dissolution media with simple models for biological lipid bilayer membranes
dissolution conditions in order to minimize for the study of drug partitioning from aqueous
practical problems, such as analytical complica- phase into the liposome.127 Several authors have
tions, and to keep the cost of the test at the suggested that this parameter correlates better
minimum value.121–123 However, if a test is with human drug absorption than n-octanol-
required that provides more information about water partition coefficient.128,129
what will happen in vivo, the BCS can simplify the
requirements of the test and provide guidance Membrane Vesicles
regarding the inferences that we can obtain from The most commonly used are Brush Border
in vitro assays.23 As mentioned previously, BCS is Membrane Vesicles (BBMV) and Basolateral
a framework for classifying drug substances based membrane vesicles (BLMV), both subcellular
on their aqueous solubility and permeability and fractions. Its preparation involves tissue homo-
provides the basis for establishing in vitro–in vivo genation and differential sedimentation, fractio-
correlations (IVIVC) and for justifying ‘‘biowaivers,’’ nation, and differential precipitation. For BLMV
or in other words, permission to use dissolution test there is an additional subfractionation step.
data as a surrogate for pharmacokinetic data. Basically, these systems are used for transcellular
Hence, a dissolution test can be used as an in vitro absorption studies130 as well as active and
bioequivalence study instead of an in vivo bioequi- facilitated transport mechanisms.131–133 The tis-
valence study. sues may be of human origin but most frequently
are derived from different animal species such us
Absorption rabbits, pigs, and rats. BBM contain a variety of
hydrolytic enzymes, which are valuable tools in
N-Octanol/Water Partition Coefficient
studying drug stability. The distribution of these
This parameter is often expressed by the Log(P) enzymes is well known134–136 enabling rational
value. The Log(P) is basically a parameter of approaches to assessing protection of the drug by
lipophilicity where the distribution between a formulation or synthetic techniques. BBM matrix
solute dissolved in an aqueous buffer (aqueous is especially useful in studying the specificity of
phase) and n-octanol, as organic phase, is targeted prodrug reconversion at the intestinal
measured.124–126 The measure of disappearance wall.137
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
672 RUIZ-GARCIA ET AL.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 673
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
674 RUIZ-GARCIA ET AL.
consumption, bile content, ATP, perfusion flow (e.g., rat liver –S9 mix) is added to simulate the
rate,...etc). effect of metabolism as some compounds, like
benzopyrene, are not mutagenic themselves but
their metabolic products are. The bacteria are
DNA Microarray Assay (DNA chips) spread on a histidine-free agar plate in the middle
DNA Microarray assays consist of a collection of which the mutagen to be tested is added. The
of microscopic DNA fragments attached to a plates are then incubated for 48 h. The muta-
support material forming an array for the purpose genicity of a substance is proportional to the
of expression profiling, monitoring expression number of colonies observed.
levels for thousands of genes simultaneously. It
allows the evaluation of expression of the mRNA COMET Assay
transcripts for a large number of genes by a single
experiment (HTS).209,210 Basically, a cell is embedded in agar and exposed
Measuring gene expression using DNA micro- to a DNA-damaging agent such as UV radiation or
arrays is relevant in metabolism studies when we a chemical mutagen. The cell is then permeabi-
are investigating whether the gene expression of lized by adding detergent and an electric field
drug enzymes involved either in phase I211 or applied. If the cell’s genomic DNA has been broken
Phase II212 metabolism is affected by a potential into small fragments then these fragments move
drug. The measurement of gene expression out of the cell by electrophoresis and form a streak
levels upon exposure to a xenobiotic may provide or ‘‘tail’’ leading away of the cell. This looks a bit
information about its mechanism of action/elim- like a comet, hence the name of the assay.
ination forming a sort of genetic signature.
Microarray applications include the identifica- Hepatotoxicity
tion of disease-associated genes,213–215 drug
target validation,216 biological pathways dissec- Hepatotoxicity can be studied through some of the
tion,217–219 discovery of gene functions,220 experi- in vitro metabolism assays described above, such
mental annotation of the human genome,221 as: liver slices, cell-based cultures, hepatocytes,
compound toxicity and safety assessment and perfused liver. Mitochondrial dysfunction is
studies,222,223 tumor classifications,224–226 diag- often detected in liver cultures234–236 since the
nostic and prognostic predictions,227–230 and other liver is the main organ in contact with xenobiotics
biomarker identification.231–233 due to its detoxifying body function and the fact
that is a very well-perfused tissue. Table 3 lists
recent published in vitro toxicity work.
Toxicity
MTT Assay
Ames Test
A colorimetric assay based on the tetrazolium salt
In the Ames test, several strains of Salmonella MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
typhimurium that carry mutations in genes tetrazolium bromide) that measures only living
involved in histidine synthesis are used. The cells and can be read on a scanning multi-well
bacteria require histidine for growth. The variable spectrophotometer.
being tested is the mutagen’s ability to cause a
reversion to growth on a histidine-free medium.
SRB Assay
The tester strains are specially constructed to
have both frame shift and point mutations in the The goal of using Sulforhodamine B is to measure
genes required to synthesize histidine, which drug-induced cytotoxicity and cell proliferation for
allows for the detection of mutagens acting via large-scale drug-screening applications. Its prin-
different mechanisms. Some compounds are quite ciple is based on the ability of the protein dye
specific, causing reversions in just one or two Sulforhodamine B to bind electrostatically in a
strains. The tester strains also carry mutations pH-dependent manner to proteins and basic
in the genes responsible for lipopolysaccharide amino acid residues of trichloroacetic acid-fixed
synthesis, making the cell wall of the bacteria cells. Under mildly acidic conditions, it binds and
more permeable, and in the excision repair system can be extracted from cells and solubilized for
to make the test more sensitive. Rat liver extract measurement.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 675
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
676 RUIZ-GARCIA ET AL.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
Table 8. Online Information and Software Resources in Pharmacokinetics/Pharmacodynamics
DOI 10.1002/jps
nonmem.cfm
ftp://ftp.globomaxnm.com/Public/nonmem/ Shared resource for files and information for the NONMEM community
http://www.pharsight.com/main.php Pharsight facilitates strategic decision making in drug development. Pharsight WINONLIN/WINONMIX
software improves the value and availability of preclinical and clinical program
data for PK/PD modeling, analysis, drug attribute visualization, reporting and
trial simulation
http://xpose.sourceforge.net/ Xpose is an R-based model building aid for population analysis using NONMEM. XPOSE
It facilitates data set checkout, exploration and visualization, model diagnostics,
candidate covariate identification and model comparison
http://www.mrc-bsu.cam.ac.uk/bugs/ The BUGS (Bayesian inference Using Gibbs Sampling) project is concerned with BUGS
flexible software for the Bayesian analysis of complex statistical models using
Markov chain Monte Carlo (MCMC) methods
http://www.exprimo.com/ Exprimo is a European consulting company with the emphasis of its activities Exprimo NV
focused towards the application of quantitative, model-based approaches at
all stages of pharmaceutical development
http://www.emf-consulting.com/ EMF Consulting is a group of pharmaceutical consultants who provide EMF Consulting
drug development services, especially related to study design, analysis and
development planning
http://www.lapp.nl/ LAP&P provides interdisciplinary support on Pharmacokinetic and LAP&P Consultants
Pharmacodynamic aspects during preclinical and clinical Drug Development
http://www.boomer.org/pkin/ The purpose of this page is to provide links to information about the discipline of
Pharmacokinetics and Pharmacodynamics
http://depts.washington.edu/rfpk/ The Resource Facility for Population Kinetics is a computer resource facility
sponsored by the National Institute of Biomedical Imaging and Bioengineering
at the National Institutes of Health
http://anesthesia.stanford.edu/pkpd/ On this server you will find PK/PD software, computer controlled drug
administration programs, and simulation programs. This server is maintained
by Steve Shafer of the Department of Anesthesia at Stanford
http://www.lapk.org/ The Laboratory of Applied Pharmacokinetics (LAPK) of the School of Medicine LAPK
at the University of Southern California is a resource for optimal study and
control of pharmacokinetic systems and for individualized drug therapy
supported in part by the National Library of Medicine (NLM) and National
Center for Research Resources
http://www.drudevo.com/ More than 20þ years experience in modeling & simulation with a special DruDev0
focus on optimizing drug development and software development
http://members.aol.com/rdppweb/index.htm Research and development for population pharmacokinetics RDPP
PHARMACOKINETICS IN DRUG DISCOVERY
(Continued)
677
Table 8. (Continued )
DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 679
GLOSSARY ACKNOWLEDGMENTS
3-D-QSAR three dimensional quantitative We wish to thank Dr. Larry Wienkers (Amgen,
structure-affinity relationship Inc, Seattle, WA) for his insightful comments and
analysis helpful advice during the writing of this review.
3S three stage analysis His expertise contributed immensely to the orga-
ANN artificial neural network nization of the appropriate references and overall
BBMV brush border membrane vesicles clarity of this work
BCS biopharmaceutics classification
system
BDDCS biopharmaceutics drug disposition REFERENCES
classification system
1. 1991. Is there a need for more precise definitions
BLMV basolateral membrane vesicles
of bioavailability? Conclusions of a consensus
CED comparative equilibrium dialysis
workshop, Munich, September 9, 1989;under the
CoMFA comparative molecular field patronage of the F.I.P. Eur J Clin Pharmacol 40:
analysis 123–126.
CYP cytochrome P 450 2. Hayes S, Dunne A, Smart T, Davis J. 2004. Inter-
ECG electrocardiogram pretation and optimization of the dissolution spe-
ED equilibrium dialysis cifications for a modified release product with an in
FDA Food and Drug Administration vivo-in vitro correlation (IVIVC). J Pharm Sci 93:
HDM hexadecane membrane 571–581.
Herg human Ether-go-go-related gene 3. Uppoor VR. 2001. Regulatory perspectives on in
IAM immobilized artificial membrane vitro (dissolution)/in vivo (bioavailability) correla-
tions. J Control Release 72:127–132.
ICH international conference of
4. Lake OA, Olling M, Barends DM. 1999. In vitro/
harmonization
in vivo correlations of dissolution data of carba-
IVIVC in vitro-in vivo correlations mazepine immediate release tablets with pharma-
NAD naı̈ve averaged data cokinetic data obtained in healthy volunteers. Eur
NADP nicotinamide adenine dinucleotide J Pharm Biopharm 48:13–19.
phosphate 5. Malinowski HJ. 1997. The role of in vitro-in vivo
NADPH reduced form of NADP correlations (IVIVC) to regulatory agencies. Adv
NCA non-compartmental analysis Exp Med Biol 423:261–268.
NDA new drug application 6. Gillespie WR. 1997. Convolution-based appro-
NPD naı̈ve pooled data aches for in vivo-in vitro correlation modeling.
ORMUCS ordered multicategorical classification Adv Exp Med Biol 423:53–65.
7. Elkoshi Z. 1999. Dissolution specifications based
method using the Simplex
on release rates. J Pharm Sci 88:434–444.
PAMPA parallel artificial membranes
8. Chen J, Ping QN, Guo JX, Chu XZ, Song MM.
permeability assay 2006. Effect of phospholipid composition on char-
PATQSAR population analysis by acterization of liposomes containing 9-nitrocamp-
topology-based QSAR tothecin. Drug Dev Ind Pharm 32:719–726.
PBPK physiologically-based 9. Lowis S, Lewis I, Elsworth A, Weston C, Doz F,
pharmacokinetics Vassal G, Bellott R, Robert J, Pein F, Ablett S,
PK pharmacokinetics Pinkerton R, Frappaz D. 2006. A phase I study of
popPK population pharmacokinetics intravenous liposomal daunorubicin (DaunoXome)
QSAR quantitative structure-affinity in paediatric patients with relapsed or resistant
relationship solid tumours. Br J Cancer 95:571–580.
10. Bedikian AY, Vardeleon A, Smith T, Campbell S,
QSPR quantitative structure-property
Namdari R. 2006. Pharmacokinetics and urinary
relationship technique
excretion of vincristine sulfate liposomes injection
S2S standard two stage approach in metastatic melanoma patients. J Clin Pharma-
SVM support vector machines col 46:727–737.
UDP uridine diphosphate 11. Mavroudis D, Kouroussis C, Kakolyris S, Agelaki
UF ultrafiltration S, Kalbakis K, Androulakis N, Souglakos J, Samonis
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
680 RUIZ-GARCIA ET AL.
G, Georgoulias V. 2002. Phase I study of paclitaxel 27. FDA Guidance for Industry. Waiver of in vivo
(taxol) and pegylated liposomal doxorubicin (cae- bioavailability and bioequivalence studies for
lyx) administered every 2 weeks in patients with immediate-release solid oral dosage forms based
advanced solid tumors. Oncology 62:216–222. on a biopharmaceutics classification systemhttp://
12. van Zuylen L, Gianni L, Verweij J, Mross K, www.fda.gov/cder/index.htm. Accesed March
Brouwer E, Loos WJ, Sparreboom A. 2000. 14th, 2004.
Inter-relationships of paclitaxel disposition, infu- 28. Klopman G, Zhu H. 2005. Recent methodologies
sion duration and cremophor EL kinetics in cancer for the estimation of n-octanol/water partition
patients. Anticancer Drugs 11:331–337. coefficients and their use in the prediction of
13. Kola I, Landis J. 2004. Can the pharmaceutical membrane transport properties of drugs. Mini
industry reduce attrition rates? Nat Rev Drug Rev Med Chem 5:127–133.
Discov 3:711–715. 29. Yoshida F, Topliss JG. 2000. QSAR model for drug
14. Development TCftSoD. 2005. ed. human oral bioavailability. J Med Chem 43:2575–
15. Fostel J. 2005. Predictive ADME-Tox London, UK, 2585.
27-28April2005. Expert Opin Drug Metab Toxicol 30. Guttendorf R. 1996. The emerging role of A.D.M.E
1:565–570. in optimizing drug discovery and design. Network
16. van de Waterbeemd H, Gifford E. 2003. ADMET in Science.
silico modelling: Towards prediction paradise? Nat 31. Donato MT, Castell JV. 2003. Strategies and
Rev Drug Discov 2:192–204. molecular probes to investigate the role of
17. O’Brien SE, de Groot MJ. 2005. Greater than the cytochrome P450 in drug metabolism: Focus on
sum of its parts: Combining models for useful in vitro studies. Clin Pharmacokinet 42:153–
ADMET prediction. J Med Chem 48:1287–1291. 178.
18. Kennedy T. 1997. Managing the drug discovery/ 32. Brandon EF, Raap CD, Meijerman I, Beijnen JH,
development interface. Drug Discovery Today 2: Schellens JH. 2003. An update on in vitro test
436–444. methods in human hepatic drug biotransforma-
19. (CDER) USDoHaHSFaDACfDEaR. 2006. Gui- tion research: Pros and cons. Toxicol Appl Phar-
dance for Industry, Investigators and Reviewers. macol 189:233–246.
Exploratory IND studies 33. Bursi R, de Gooyer ME, Grootenhuis A, Jacobs PL,
20. Kansy M, Senner F, Gubernator K. 1998. Physi- van der Louw J, Leysen D. 2001. (Q) SAR study on
cochemical high throughput screening: Parallel the metabolic stability of steroidal androgens.
artificial membrane permeation assay in the J Mol Graph Model 19:552–556, 607–608.
description of passive absorption processes. 34. de Groot MJ. 2006. Designing better drugs: Pre-
J Med Chem 41:1007–1010. dicting cytochrome P450 metabolism. Drug Discov
21. (CDER) USDoHaHSFaDACfDEaR. 2003. Bioa- Today 11:601–606.
vailability and bioequivalence studies for orally 35. Joukhadar C, Muller M. 2005. Microdialysis: Cur-
administered drug products—General considera- rent applications in clinical pharmacokinetic stu-
tions. dies and its potential role in the future. Clin
22. Amidon GL, Lennernas H, Shah VP, Crison JR. Pharmacokinet 44:895–913.
1995. A theoretical basis for a biopharmaceutic 36. Eriksson MA, Gabrielsson J, Nilsson LB. 2005.
drug classification: The correlation of in vitro drug Studies of drug binding to plasma proteins using
product dissolution and in vivo bioavailability. a variant of equilibrium dialysis. J Pharm Biomed
Pharm Res 12:413–420. Anal 38:381–389.
23. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, 37. Pacifici GM, Viani A. 1992. Methods of determin-
Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, ing plasma and tissue binding of drugs. Pharma-
Hussain AS. 2002. Biopharmaceutics classifica- cokinetic consequences. Clin Pharmacokinet 23:
tion system: The scientific basis for biowaiver 449–468.
extensions. Pharm Res 19:921–925. 38. Muller L, Kikuchi Y, Probst G, Schechtman L,
24. CDER/FDA. 1995. November 1995 Guidance for Shimada H, Sofuni T, Tweats D. 1999. ICH-har-
industry, Immediate Release Solid Oral Dosage monised guidances on genotoxicity testing of phar-
Forms: Scale-Up and Post-Approval Changes maceuticals: Evolution, reasoning and impact.
25. Sun H. 2005. A naive bayes classifier for prediction Mutat Res 436:195–225.
of multidrug resistance reversal activity on the 39. Ashby J. 1992. Use of short-term tests in deter-
basis of atom typing. J Med Chem 48:4031–4039. mining the genotoxicity or nongenotoxicity of che-
26. Wu CY, Benet LZ. 2005. Predicting drug disposi- micals. IARC Sci Publ 116:135–164.
tion via application of BCS: Transport/absorption/ 40. Sorsa M. EncyclopaediaofOccupationalHelathand
elimination interplay and development of a bio- Safety. GenotoxicChemicals.
pharmaceutics drug disposition classification sys- 41. Ames BN, McCann J, Yamasaki E. 1975. Methods
tem. Pharm Res 22:11–23. for detecting carcinogens and mutagens with the
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 681
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
682 RUIZ-GARCIA ET AL.
1998. Inhibition of monoamine oxidase by pirlin- 81. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz
dole analogues: 3D-QSAR and CoMFA analysis. EG, Lan LB, Yasuda K, Shepard RL, Winter
J Chem Inf Comput Sci 38:1137–1144. MA, Schuetz JD, Wikel JH, Wrighton SA. 2002.
68. Swaan PW, Szoka FC Jr, Oie S. 1997. Molecular Application of three-dimensional quantitative
modeling of the intestinal bile acid carrier: structure-activity relationships of P-glycoprotein
A comparative molecular field analysis study. inhibitors and substrates. Mol Pharmacol 61:974–
J Comput Aided Mol Des 11:581–588. 981.
69. Cianchetta G, Li Y, Kang J, Rampe D, Fravolini A, 82. Penzotti JE, Lamb ML, Evensen E, Grootenhuis
Cruciani G, Vaz RJ. 2005. Predictive models for PD. 2002. A computational ensemble pharmaco-
hERG potassium channel blockers. Bioorg Med phore model for identifying substrates of P-glyco-
Chem Lett 15:3637–3642. protein. J Med Chem 45:1737–1740.
70. Swaan PW, Koops BC, Moret EE, Tukker JJ. 1998. 83. Rao GS, Ramachandran MV, Bajaj JS. 2006.
Mapping the binding site of the small intestinal In silico structure-based design of a potent and
peptide carrier (PepT1) using comparative mole- selective small peptide inhibitor of protein tyro-
cular field analysis. Receptors Channels 6:189– sine phosphatase 1B, a novel therapeutic target for
200. obesity and type 2 diabetes mellitus: A computer
71. Pajeva I, Wiese M. 1998. Molecular modeling of modeling approach. J Biomol Struct Dyn 23:377–
phenothiazines and related drugs as multidrug 384.
resistance modifiers: A comparative molecular 84. Yoshitani N, Satou K, Saito K, Suzuki S, Hata-
field analysis study. J Med Chem 41:1815–1826. naka H, Seki M, Shinozaki K, Hirota H, Yokoyama
72. Singh SK, Dessalew N, Bharatam PV. 3D-QSAR S. 2005. A structure-based strategy for discovery of
CoMFA study on indenopyrazole derivatives as small ligands binding to functionally unknown
cyclin dependent kinase 4 (CDK4) and cyclin proteins: Combination of in silico screening and
dependent kinase 2 (CDK2) inhibitors. Eur J surface plasmon resonance measurements. Pro-
Med Chem 41:1310–1319. teomics 5:1472–1480.
73. López de Briñas ELJ, Centeno NB, Segura J, 85. Matyas G, Arnold E, Carrel T, Baumgartner D,
González-Merino ML, de la Torre R, Sanz F. Boileau C, Berger W, Steinmann B. 2006. Identi-
2000. Pharmacophore development for the inter- fication and in silico analyses of novel TGFBR1
action of cytochrome P450 1A2 with its substrates and TGFBR2 mutations in Marfan syndrome-
and inhibitors edition. New York: Kluwer Aca- related disorders. Hum Mutat 27:760–769.
demic/Plenum Publishers. pp 141–146. 86. Miguet L, Zhang Z, Barbier M, Grigorov MG.
74. de Groot MJ, Alex AA, Jones BC. 2002. Develop- 2006. Comparison of a homology model and
ment of a combined protein and pharmacophore the crystallographic structure of human 11beta-
model for cytochrome P450 2 C9. J Med Chem 45: hydroxysteroid dehydrogenase type 1 (11beta
1983–1993. HSD1) in a structure-based identification of inhi-
75. Boyer S, Zamora I. 2002. New methods in predic- bitors. J Comput Aided Mol Des 20:67–81.
tive metabolism. J Comput Aided Mol Des 16:403– 87. Yu J, Paine MJ, Marechal JD, Kemp CA, Ward CJ,
413. Brown S, Sutcliffe MJ, Roberts GC, Rankin EM,
76. Snyder Richard, Sangar Rajesh, Wang Jibo, Ekins Wolf CR. 2006. In silico prediction of drug binding
Sean. 2002. Three-dimensional quantitative struc- to CYP2 D6: Identification of a new metabolite of
ture activity relationship for Cyp2d6 substrates. metoclopramide. Drug Metab Dispos 34:1386–
Quant Structure-Activity Relationship 21:357– 1392.
368. 88. Prosser DE, Guo Y, Jia Z, Jones G. 2006. Struc-
77. Egnell AC, Houston JB, Boyer CS. 2005. Predic- tural motif-based homology modeling of CYP27A1
tive models of CYP3A4 heteroactivation: In vitro- and site-directed mutational analyses affecting
in vivo scaling and pharmacophore modeling. vitamin D hydroxylation. Biophys J 90:3389–3409.
J Pharmacol Exp Ther 312:926–937. 89. Wang Q, Halpert JR. 2002. Combined three-
78. Ekins S, Stresser DM, Williams JA. 2003. dimensional quantitative structure-activity rela-
In vitro and pharmacophore insights into CYP3A tionship analysis of cytochrome P450 2B6 sub-
enzymes. Trends Pharmacol Sci 24:161–166. strates and protein homology modeling. Drug
79. Tanaka T, Okuda T, Yamamoto Y. 2004. Charac- Metab Dispos 30:86–95.
terization of the CYP3A4 active site by homology 90. Lewis DF, Ito Y, Goldfarb PS. 2006. Investigating
modeling. Chem Pharm Bull (Tokyo) 52:830–835. human P450s involved in drug metabolism via
80. Ekins S, Ring BJ, Bravi G, Wikel JH, Wrighton homology with high-resolution P450 crystal struc-
SA. 2000. Predicting drug-drug interactions in tures of the CYP2C subfamily. Curr Drug Metab
silico using pharmacophores: A paradigm for the 7:589–598.
next millenium, edition. La Jolla, CA: Interna- 91. Lee H, Yeom H, Kim YG, Yoon CN, Jin C, Choi JS,
tional University Line. pp 269–299. Kim BR, Kim DH. 1998. Structure-related inhibi-
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 683
tion of human hepatic caffeine N3-demethylation 105. Sutton SC, Hu M. 2006. An automated process for
by naturally occurring flavonoids. Biochem Phar- building reliable and optimal in vitro/in vivo cor-
macol 55:1369–1375. relation models based on Monte Carlo simulations.
92. Altomare C, Cellamare S, Summo L, Catto M, Aaps J 8:E307–313.
Carotti A, Thull U, Carrupt PA, Testa B, 106. Kortejarvi H, Malkki J, Marvola M, Urtti A, Yli-
Stoeckli-Evans H. 1998. Inhibition of monoamine perttula M, Pajunen P. 2006. Level A in vitro-in
oxidase-B by condensed pyridazines and pyrimi- vivo correlation (IVIVC) model with Bayesian
dines: Effects of lipophilicity and structure-activ- approach to formulation series. J Pharm Sci 95:
ity relationships. J Med Chem 41:3812–3820. 1595–1605.
93. Campbell NR, Van Loon JA, Sundaram RS, Ames 107. Dahl SG, Sylte I. 2006. From genomics to drug
MM, Hansch C, Weinshilboum R. 1987. Human targets. J Psychopharmacol 20:95–99.
and rat liver phenol sulfotransferase: Structure- 108. Thompson MC, Fuller C, Hogg TL, Dalton J, Fin-
activity relationships for phenolic substrates. Mol kelstein D, Lau CC, Chintagumpala M, Adesina A,
Pharmacol 32:813–819. Ashley DM, Kellie SJ, Taylor MD, Curran T,
94. Mercier C, Fabart V, Sobel Y, Dubois JE. 1991. Gajjar A, Gilbertson RJ. 2006. Genomics identifies
Modeling alcohol metabolism with the DARC/ medulloblastoma subgroups that are enriched for
CALPHI system. J Med Chem 34:934–942. specific genetic alterations. J Clin Oncol 24:1924–
95. Mercier CSY, Dubois JE. 1992. DARC/PELCO 1931.
method: A topological tool for QSAR search and 109. He YD. 2006. Genomic approach to biomarker
its reliable predictive capability. Philadelphia: identification and its recent applications. Cancer
Gordon and Breach. pp 199–257. Biomark 2:103–133.
96. Hansch C, Leo A, Mekapati SB, Kurup A. 2004. 110. Anderson NL, Anderson NG. 1998. Proteome and
QSAR and ADME. Bioorg Med Chem 12:3391– proteomics: New technologies, new concepts, and
3400. new words. Electrophoresis 19:1853–1861.
97. Karelson M, Lobanov VS, Katritzky AR. 1996. 111. Blackstock WP, Weir MP. 1999. Proteomics:
Quantum-chemical descriptors in QSAR/QSPR Quantitative and physical mapping of cellular
studies. Chem Rev 96:1027–1044. proteins. Trends Biotechnol 17:121–127.
98. Katritzky AR, Kuanar M, Fara DC, Karelson M, 112. Kennedy S. 2002. The role of proteomics in tox-
Acree WE Jr. 2004. QSPR treatment of rat blood:- icology: Identification of biomarkers of toxicity by
air, saline:air and olive oil:air partition coefficients protein expression analysis. Biomarkers 7:269–
using theoretical molecular descriptors. Bioorg 290.
Med Chem 12:4735–4748. 113. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM,
99. Katritzky AR, Petrukhin R, Jain R, Karelson M. Chiu JF. 2004. Diverse proteomic alterations in
2001. QSPR analysis of flash points. J Chem Inf gastric adenocarcinoma. Proteomics 4:3276–3287.
Comput Sci 41:1521–1530. 114. Somiari RI, Sullivan A, Russell S, Somiari S, Hu
100. Bermejo M, Merino V, Garrigues TM, Pla Delfina H, Jordan R, George A, Katenhusen R, Bucho-
JM, Mulet A, Vizet P, Trouiller G, Mercier C. 1999. wiecka A, Arciero C, Brzeski H, Hooke J, Shriver
Validation of a biophysical drug absorption model C. 2003. High-throughput proteomic analysis of
by the PATQSAR system. J Pharm Sci 88:398– human infiltrating ductal carcinoma of the breast.
405. Proteomics 3:1863–1873.
101. Tantishaiyakul V. 2005. Prediction of the aqueous 115. O’Driscoll L, Clynes M. 2006. Biomarkers and
solubility of benzylamine salts using QSPR model. multiple drug resistance in breast cancer. Curr
J Pharm Biomed Anal 37:411–415. Cancer Drug Targets 6:365–384.
102. Wedge D, Ingram D, McLean D, Mingham C, 116. Abdi F, Quinn JF, Jankovic J, McIntosh M, Lever-
Bandar Z. 2006. On global-local artificial neural enz JB, Peskind E, Nixon R, Nutt J, Chung K,
networks for function approximation. IEEE Trans Zabetian C, Samii A, Lin M, Hattan S, Pan C,
Neural Netw 17:942–952. Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D,
103. Engkvist O, Wrede P. 2002. High-throughput, in Montine TJ, Zhang J. 2006. Detection of biomar-
silico prediction of aqueous solubility based on kers with a multiplex quantitative proteomic plat-
one- and two-dimensional descriptors. J Chem form in cerebrospinal fluid of patients with
Inf Comput Sci 42:1247–1249. neurodegenerative disorders. J Alzheimers Dis
104. Li H, Yap CW, Xue Y, Li ZR, Ung CY, Han LY, 9:293–348.
Han YZ, Chen YZ. 2005. Statistical learning 117. Diamond DL, Proll SC, Jacobs JM, Chan EY,
approach for predicting specific pharmacody- Camp DG 2nd, Smith RD, Katze MG. 2006. Hepa-
namic, pharmacokinetic, or toxicological proper- toProteomics: Applying proteomic technologies to
ties of pharmaceutical agents. Drug Develop Res the study of liver function and disease. Hepatology
66:245–259. 44:299–308.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
684 RUIZ-GARCIA ET AL.
118. Williams RE, Lenz EM, Lowden JS, Rantalainen 131. Stevens BR, Ross HJ, Wright EM. 1982. Multiple
M, Wilson ID. 2005. The metabonomics of aging transport pathways for neutral amino acids in
and development in the rat: An investigation into rabbit jejunal brush border vesicles. J Membr Biol
the effect of age on the profile of endogenous 66:213–225.
metabolites in the urine of male rats using (1)H 132. Dudeja PK, Harig JM, Wali RK, Knaup SM,
NMR and HPLC-TOF MS. Mol Biosyst 1:166– Ramaswamy K, Brasitus TA. 1991. Differential
175. modulation of human small intestinal brush-
119. Robertson DG, Reily MD, Baker JD. 2005. Meta- border membrane hemileaflet fluidity affects
bonomics in preclinical drug development. Expert leucine aminopeptidase activity and transport
Opin Drug Metab Toxicol 1:363–376. of D-glucose and L-glutamate. Arch Biochem
120. Craig A, Sidaway J, Holmes E, Orton T, Jackson Biophys 284: 338–345.
D, Rowlinson R, Nickson J, Tonge R, Wilson I, 133. Yao HM, Chiou WL. 2006. The complexity of
Nicholson J. 2006. Systems toxicology: Integrated intestinal absorption and exsorption of digoxin
genomic, proteomic and metabonomic analysis of in rats. Int J Pharm 322:79–86.
methapyrilene induced hepatotoxicity in the rat. 134. Harrison DD, Webster HL. 1971. Proximal to dis-
J Proteome Res 5:1586–1601. tal variations in enzymes of the rat intestine.
121. Pedraza A, Sicilia MD, Rubio S, Perez-Bendito D. Biochim Biophys Acta 244:432–436.
2006. Pharmaceutical quality control of acid and 135. Bai JP. 1993. Distribution of brush-border mem-
neutral drugs based on competitive self-assembly brane peptidases along the rabbit intestine: Impli-
in amphiphilic systems. Analyst 131:81–89. cation for oral delivery of peptide drugs. Life Sci
122. Bamiro OA, Odeniyi MA, Idowu OB, Jaiyeoba KT. 52:941–947.
2004. Physicochemical equivalence of chloroquine 136. Tobey N, Heizer W, Yeh R, Huang TI, Hoffner C.
phosphate tablets. Afr J Med Med Sci 33:371– 1985. Human intestinal brush border peptidases.
375. Gastroenterology 88:913–926.
123. Garcia CV, Paim CS, Steppe M, Schapoval EE. 137. TenHoor CN, Stewart BH. 1995. Reconversion of
2006. Development and validation of a dissolution fosphenytoin in the presence of intestinal alkaline
test for rabeprazole sodium in coated tablets. phosphatase. Pharm Res 12:1806–1809.
J Pharm Biomed Anal 41:833–837. 138. Stewart BH, Chan OH, Lu RH, Reyner EL,
124. Merino V, Freixas J, del Val Bermejo M, Garrigues Schmid HL, Hamilton HW, Steinbaugh BA, Taylor
TM, Moreno J, Pla-Delfina JM. 1995. Biophysical MD. 1995. Comparison of intestinal permeabilities
models as an approach to study passive absorption determined in multiple in vitro and in situ models:
in drug development: 6-fluoroquinolones. J Pharm Relationship to absorption in humans. Pharm Res
Sci 84:777–782. 12:693–699.
125. Bermejo M, Avdeef A, Ruiz A, Nalda R, Ruell JA, 139. Leppert PS, Fix JA. 1994. Use of everted intestinal
Tsinman O, Gonzalez I, Fernandez C, Sanchez G, rings for in vitro examination of oral absorption
Garrigues TM, Merino V. 2004. PAMPA–a drug potential. J Pharm Sci 83:976–981.
absorption in vitro model 7. Comparing rat in situ, 140. Artursson P, Ungell AL, Lofroth JE. 1993. Selec-
Caco-2, and PAMPA permeability of fluoroquino- tive paracellular permeability in two models of
lones. Eur J Pharm Sci 21:429–441. intestinal absorption: Cultured monolayers of
126. van De Waterbeemd H, Smith DA, Beaumont K, human intestinal epithelial cells and rat intestinal
Walker DK. 2001. Property-based design: Optimi- segments. Pharm Res 10:1123–1129.
zation of drug absorption and pharmacokinetics. 141. Wohnsland F, Faller B. 2001. High-throughput
J Med Chem 44:1313–1333. permeability pH profile and high-throughput
127. Edward HK. 2001. High throughput physicochem- alkane/water log P with artificial membranes.
ical profiling for drug discovery. J Pharma Sci J Med Chem 44:923–930.
90:1838–1858. 142. Matsson P, Bergstrom CA, Nagahara N, Tavelin S,
128. Balon K, Riebesehl BU, Muller BW. 1999. Drug Norinder U, Artursson P. 2005. Exploring the role
liposome partitioning as a tool for the prediction of of different drug transport routes in permeability
human passive intestinal absorption. Pharm Res screening. J Med Chem 48:604–613.
16:882–888. 143. Ruell JA, Tsinman KL, Avdeef A. 2003. PAMPA—
129. Avdeef A, Box KJ, Comer JE, Hibbert C, Tam KY. a drug absorption in vitro model. 5. Unstirred
1998. pH-metric logP 10. Determination of liposo- water layer in iso-pH mapping assays and pKa
mal membrane-water partition coefficients of (flux)—optimized design (pOD-PAMPA). Eur
ionizable drugs. Pharm Res 15:209–215. J Pharm Sci 20:393–402.
130. Stewart BH, Chan OH, Jezyk N, Fleisher D. 1997. 144. Sugano K, Hamada H, Machida M, Ushio H,
Discrimination between drug candidates using Saitoh K, Terada K. 2001. Optimized conditions
models for evaluation of intestinal absorption. of bio-mimetic artificial membrane permeation
Adv Drug Delivery Rev 23:27–45. assay. Int J Pharm 228:181–188.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 685
145. Matsumoto S, Saito H, Inui K. 1994. Transcellular immobilized artificial membrane chromatogra-
transport of oral cephalosporins in human intest- phy. J Chromatogr A 721:213–230.
inal epithelial cells, Caco-2: Interaction with 159. Lazaro E, Rafols C, Abraham MH, Roses M. 2006.
dipeptide transport systems in apical and basolat- Chromatographic estimation of drug disposition
eral membranes. J Pharmacol Exp Ther 270:498– properties by means of immobilized artificial
504. membranes (IAM) and C18 columns. J Med Chem
146. Dantzig AH, Hoskins JA, Tabas LB, Bright S, 49:4861–4870.
Shepard RL, Jenkins IL, Duckworth DC, Sports- 160. Rodriguez-Ibanez M, Sanchez-Castano G, Monta-
man JR, Mackensen D, Rosteck PR Jr, et al. 1994. lar-Montero M, Garrigues TM, Bermejo M, Merino
Association of intestinal peptide transport with a V. 2006. Mathematical modelling of in situ and in
protein related to the cadherin superfamily. vitro efflux of ciprofloxacin and grepafloxacin. Int
Science 264:430–433. J Pharm 307:33–41.
147. Hunter J, Jepson MA, Tsuruo T, Simmons NL, 161. Fernandez-Teruel C, Gonzalez-Alvarez I, Casabo
Hirst BH. 1993. Functional expression of P-glyco- VG, Ruiz-Garcia A, Bermejo M. 2005. Kinetic
protein in apical membranes of human intestinal modelling of the intestinal transport of saraflox-
Caco-2 cells. Kinetics of vinblastine secretion and acin. Studies in situ in rat and in vitro in Caco-2
interaction with modulators. J Biol Chem 268: cells. J Drug Target 13:199–212.
14991–14997. 162. Ferrando R, Garrigues TM, Bermejo MV, Martin-
148. Phung-Ba V, Warnery A, Scherman D, Wils P. Algarra R, Merino V, Polache A. 1999. Effects of
1995. Interaction of pristinamycin IA with ethanol on intestinal absorption of drugs: In situ
P-glycoprotein in human intestinal epithelial studies with ciprofloxacin analogs in acute and
cells. Eur J Pharmacol 288:187–192. chronic alcohol-fed rats. Alcohol Clin Exp Res
149. Dean M, Allikmets R. 1995. Evolution of ATP- 23:1403–1408.
binding cassette transporter genes. Curr Opin 163. Doluisio JT, Billups NF, Dittert LW, Sugita ET,
Genet Dev 5:779–785. Swintosky JV. 1969. Drug absorption. I. An in situ
150. Higgins CF. 1992. ABC transporters: From micro- rat gut technique yielding realistic absorption
organisms to man. Annu Rev Cell Biol 8:67–113. rates. J Pharm Sci 58:1196–1200.
151. Dean M, Rzhetsky A, Allikmets R. 2001. The 164. Patel N, Forbes B, Eskola S, Murray J. 2006.
human ATP-binding cassette (ABC) transporter Use of simulated intestinal fluids with Caco-2 cells
superfamily. Genome Res 11:1156–1166. and rat ileum. Drug Dev Ind Pharm 32:151–
152. Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, 161.
Scieszka JF. 1989. The Madin Darby canine kid- 165. Carr G, Haslam IS, Simmons NL. 2006. Voltage
ney (MDCK) epithelial cell monolayer as a model dependence of transepithelial guanidine permea-
cellular transport barrier. Pharm Res 6:71–77. tion across Caco-2 epithelia allows determination
153. Irvine JD, Takahashi L, Lockhart K, Cheong J, of the paracellular flux component. Pharm Res 23:
Tolan JW, Selick HE, Grove JR. 1999. MDCK 540–548.
(Madin-Darby canine kidney) cells: A tool for 166. Hocht C, Opezzo JA, Taira CA. 2004. Microdialysis
membrane permeability screening. J Pharm Sci in drug discovery. Curr Drug Discov Technol
88:28–33. 1:269–285.
154. Li H, Chung SJ, Shim CK. 2002. Characterization 167. Brunner M, Langer O. 2006. Microdialysis versus
of the transport of uracil across Caco-2 and LLC- other techniques for the clinical assessment of
PK1 cell monolayers. Pharm Res 19:1495–1501. in vivo tissue drug distribution. Aaps J 8:E263–
155. Pidgeon C, Ong S, Liu H, Qiu X, Pidgeon M, E271.
Dantzig AH, Munroe J, Hornback WJ, Kasher 168. Islinger F, Dehghanyar P, Sauermann R, Burger
JS, Glunz L, et al. 1995. IAM chromatography: C, Kloft C, Muller M, Joukhadar C. 2006. The
An in vitro screen for predicting drug membrane effect of food on plasma and tissue concentrations
permeability. J Med Chem 38:590–594. of linezolid after multiple doses. Int J Antimicrob
156. Ong S, Liu H, Pidgeon C. 1996. Immobilized- Agents 27:108–112.
artificial-membrane chromatography: Measure- 169. Barrail A, Le Tiec C, Paci-Bonaventure S, Furlan
ments of membrane partition coefficient and V, Vincent I, Taburet AM. 2006. Determination of
predicting drug membrane permeability. amprenavir total and unbound concentrations in
J Chromatogr A 728:113–128. plasma by high-performance liquid chromatogra-
157. Ong S, Liu H, Qiu X, Bhat G, Pidgeon C. 1995. phy and ultrafiltration. Ther Drug Monit 28:89–
Membrane partition coefficients chromatographi- 94.
cally measured using immobilized artificial mem- 170. Olsen H, Andersen A, Nordbo A, Kongsgaard UE,
brane surfaces. Anal Chem 67:755–762. Bormer OP. 2004. Pharmaceutical-grade albumin:
158. Pidgeon C, Cai SJ, Bernal C. 1996. Mobile phase Impaired drug-binding capacity in vitro. BMC
effects on membrane protein elution during Clin Pharmacol 4:4.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
686 RUIZ-GARCIA ET AL.
171. Fung EN, Chen YH, Lau YY. 2003. Semi-auto- 183. Roy P, Yu LJ, Crespi CL, Waxman DJ. 1999.
matic high-throughput determination of plasma Development of a substrate-activity based
protein binding using a 96-well plate filtrate approach to identify the major human liver P-
assembly and fast liquid chromatography-tandem 450 catalysts of cyclophosphamide and ifosfamide
mass spectrometry. J Chromatogr B Analyt Tech- activation based on cDNA-expressed activities and
nol Biomed Life Sci 795:187–194. liver microsomal P-450 profiles. Drug Metab Dis-
172. Lin JH, Cocchetto DM, Duggan DE. 1987. Protein pos 27:655–666.
binding as a primary determinant of the clinical 184. Harrigan JA, McGarrigle BP, Sutter TR, Olson
pharmacokinetic properties of non-steroidal anti- JR. 2006. Tissue specific induction of cytochrome
inflammatory drugs. Clin Pharmacokinet 12:402– P450 (CYP) 1A1 and 1B1 in rat liver and lung
432. following in vitro (tissue slice) and in vivo expo-
173. Taavitsainen P, Kiukaanniemi K, Pelkonen O. sure to benzo(a)pyrene. Toxicol In Vitro 20:426–
2000. In vitro inhibition screening of human hepa- 438.
tic P450 enzymes by five angiotensin-II receptor 185. Bordelon NR, Chhabra R, Bucher JR. 2005.
antagonists. Eur J Clin Pharmacol 56:135–140. A review of evidence from short-term studies lead-
174. Bhoopathy S, Xin B, Unger SE, Karnes HT. 2005. ing to the prediction that diazoaminobenzene (1,3-
A novel incubation direct injection LC/MS/MS diphenyltriazine) is a carcinogen. J Appl Toxicol
technique for in vitro drug metabolism screening 25:514–521.
studies involving the CYP 2D6 and the CYP 3A4 186. Persson KP, Ekehed S, Otter C, Lutz ES, McPheat
isozymes. J Pharm Biomed Anal 37:739–749. J, Masimirembwa CM, Andersson TB. 2006. Eva-
175. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O. luation of human liver slices and reporter gene
2005. Multiple P450 substrates in a single run: assays as systems for predicting the cytochrome
Rapid and comprehensive in vitro interaction p450 induction potential of drugs in vivo in
assay. Eur J Pharm Sci 24:123–132. humans. Pharm Res 23:56–69.
176. Brill SS, Furimsky AM, Ho MN, Furniss MJ, Li Y, 187. Walle T, Otake Y, Galijatovic A, Ritter JK, Walle
Green AG, Bradford WW, Green CE, Kapetanovic UK. 2000. Induction of UDP-glucuronosyltrans-
IM, Iyer LV. 2006. Glucuronidation of trans- ferase UGT1A1 by the flavonoid chrysin in the
resveratrol by human liver and intestinal micro- human hepatoma cell line he p G2. Drug Metab
somes and UGT isoforms. J Pharm Pharmacol Dispos 28:1077–1082.
58:469–479. 188. O’Brien NM, Woods JA, Aherne SA, O’Callaghan
177. Galetin A, Houston JB. 2006. Intestinal and hepa- YC. 2000. Cytotoxicity, genotoxicity and oxidative
tic metabolic activity of five cytochrome p450 reactions in cell-culture models: Modulatory
enzymes: Impact on prediction of first-pass meta- effects of phytochemicals. Biochem Soc Trans
bolism. J Pharmacol Exp Ther 318:1220–1229. 28:22–26.
178. Govoni M, Casagrande S, Maucci R, Chiroli V, 189. O’Brien T, Babcock G, Cornelius J, Dingeldein M,
Tocchetti P. 2006. In vitro metabolism of (nitroox- Talaska G, Warshawsky D, Mitchell K. 2000.
y)butyl ester nitric oxide-releasing compounds: A comparison of apoptosis and necrosis induced
Comparison with glyceryl trinitrate. J Pharmacol by hepatotoxins in HepG2 cells. Toxicol Appl Phar-
Exp Ther 317:752–761. macol 164:280–290.
179. Shimada H, Miura K, Imamura Y. 2006. Charac- 190. O’Leary KA, Day AJ, Needs PW, Mellon FA,
teristics and inhibition by flavonoids of 20alpha- O’Brien NM, Williamson G. 2003. Metabolism
hydroxysteroid dehydrogenase activity in mouse of quercetin-7- and quercetin-3-glucuronides by
tissues. Life Sci 78:2931–2936. an in vitro hepatic model: The role of human
180. Wu D, George TG, Hurh E, Werbovetz KA, Dalton beta-glucuronidase, sulfotransferase, catechol-O-
JT. 2006. Pre-systemic metabolism prevents methyltransferase and multi-resistant protein
in vivo antikinetoplastid activity of N1, N4- 2 (MRP2) in flavonoid metabolism. Biochem Phar-
substituted 3,5-dinitro sulfanilamide, GB-II-150. macol 65:479–491.
Life Sci 79:1081–1093. 191. Tan YL, Goh D, Ong ES. 2006. Investigation
181. Brandon EF, Sparidans RW, Guijt KJ, Lowenthal of differentially expressed proteins due to the
S, Meijerman I, Beijnen JH, Schellens JH. 2006. inhibitory effects of berberine in human liver
In vitro characterization of the human biotrans- cancer cell line HepG2. Mol Biosyst 2:250–
formation and CYP reaction phenotype of ET-743 258.
(Yondelis, Trabectidin), a novel marine anti- 192. Takahashi S, Takahashi T, Mizobuchi S, Matsumi
cancer drug. Invest New Drugs 24:3–14. M, Yokoyama M, Morita K, Miyazaki M, Namba
182. Maron DM, Ames BN. 1983. Revised methods for M, Akagi R, Sassa S. 2003. CYP2E1 overexpres-
the Salmonella mutagenicity test. Mutat Res 113: sion up-regulates both non-specific delta-aminole-
173–215. vulinate synthase and heme oxygenase-1 in the
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 687
human hepatoma cell line HLE/2 E1. Int J Mol in primary culture of hepatocytes from chimeric
Med 11:57–62. mice with humanized liver. Drug Metab Pharma-
193. Takahashi S, Takahashi T, Mizobuchi S, Matsumi cokinet 20:121–126.
M, Morita K, Miyazaki M, Namba M, Akagi R, 204. Tomera JF, Skipper PL, Wishnok JS, Tannen-
Hirakawa M. 2002. Increased cytotoxicity of car- baum SR, Brunengraber H. 1984. Inhibition of
bon tetrachloride in a human hepatoma cell line N-nitrosodimethylamine metabolism by ethanol
overexpressing cytochrome P450 2 E1. J Int Med and other inhibitors in the isolated perfused rat
Res 30:400–405. liver. Carcinogenesis 5:113–116.
194. Hibasami H, Iwase H, Yoshioka K, Takahashi H. 205. Strubelt O, Deters M, Pentz R, Siegers CP, Younes
2006. Glycyrrhetic acid (a metabolic substance M. 1999. The toxic and metabolic effects of 23
and aglycon of glycyrrhizin) induces apoptosis in aliphatic alcohols in the isolated perfused rat liver.
human hepatoma, promyelotic leukemia and sto- Toxicol Sci 49:133–142.
mach cancer cells. Int J Mol Med 17:215–219. 206. Deters M, Strubelt O, Younes M. 1997. Reevalua-
195. Gomez-Lechon MJ, Donato T, Jover R, Rodriguez tion of cyclosporine induced hepatotoxicity in the
C, Ponsoda X, Glaise D, Castell JV, Guguen-Guil- isolated perfused rat liver. Toxicology 123:197–
louzo C. 2001. Expression and induction of a large 206.
set of drug-metabolizing enzymes by the highly 207. Wu WN, McKown LA, Yorgey KA, Pritchard JF.
differentiated human hepatoma cell line BC2. Eur 1999. In vitro metabolic products of RWJ-34130,
J Biochem 268:1448–1459. an antiarrythmic agent, in rat liver preparations.
196. Fabre N, Arrivet E, Trancard J, Bichet N, Roome J Pharm Biomed Anal 20:687–695.
NO, Prenez A, Vericat JA. 2003. A new hepatoma 208. Gawronska-Szklarz B, Musial HD, Loniewski I,
cell line for toxicity testing at repeated doses. Cell Paprota B, Drozdzik M. 2006. Lidocaine metabo-
Biol Toxicol 19:71–82. lism in isolated perfused liver from streptozotocin-
197. Paganelli G, Magnani P, Zito F, Lucignani G, induced diabetic rats. J Pharm Pharmacol 58:
Sudati F, Truci G, Motti E, Terreni M, Pollo B, 1073–1077.
Giovanelli M, et al. 1994. Pre-targeted immuno- 209. Knudsen H. 2004. Guide to Analysis of DNA
detection in glioma patients: Tumour localization Microarray Data, edition. New York: John Wiley
and single-photon emission tomography imaging and Sons Inc.
of [99mTc]PnAO-biotin. Eur J Nucl Med 21:314– 210. Schulze A, Downward J. 2001. Navigating gene
321. expression using microarrays [mdash] a technol-
198. O’Connor JE, Martinez A, Castell JV, ogy review. Nat Cell Biol 3:E190–E195.
Gomez-Lechon MJ. 2005. Multiparametric char- 211. Ejiri N, Katayama K, Kiyosawa N, Baba Y, Doi K.
acterization by flow cytometry of flow-sorted 2005. Microarray analysis on CYPs expression in
subpopulations of a human hepatoma cell line pregnant rats after treatment with pregnenolone-
useful for drug research. Cytometry A 63:48–58. 16alpha-carbonitrile and phenobarbital. Exp Mol
199. Pham TN, Marion M, Denizeau F, Jumarie C. Pathol 78:71–77.
2006. Cadmium-induced apoptosis in rat hepato- 212. Ejiri N, Katayama K, Kiyosawa N, Baba Y, Doi K.
cytes does not necessarily involve caspase- 2005. Microarray analysis on Phase II drug meta-
dependent pathways. Toxicol In Vitro bolizing enzymes expression in pregnant rats after
200. Kane BJ, Zinner MJ, Yarmush ML, Toner M. treatment with pregnenolone-16alpha-carbonitrile
2006. Liver-specific functional studies in a micro- or phenobarbital. Exp Mol Pathol 79:272–277.
fluidic array of primary Mammalian hepatocytes. 213. Chee M, Yang R, Hubbell E, Berno A, Huang XC,
Anal Chem 78:4291–4298. Stern D, Winkler J, Lockhart DJ, Morris MS,
201. Yamazaki H, Oda Y, Funae Y, Imaoka S, Inui Y, Fodor SP. 1996. Accessing genetic information
Guengerich FP, Shimada T. 1992. Participation of with high-density DNA arrays. Science 274:610–
rat liver cytochrome P450 2E1 in the activation of 614.
N-nitrosodimethylamine and N-nitrosodiethyla- 214. Heller RA, Schena M, Chai A, Shalon D, Bedilion
mine to products genotoxic in an acetyltransfer- T, Gilmore J, Woolley DE, Davis RW. 1997. Dis-
ase-overexpressing Salmonella typhimurium covery and analysis of inflammatory disease-
strain (NM2009). Carcinogenesis 13:979–985. related genes using cDNA microarrays. Proc Natl
202. Elaut G, Henkens T, Papeleu P, Snykers S, Vinken Acad Sci U S A 94: 2150–2155.
M, Vanhaecke T, Rogiers V. 2006. Molecular 215. Zhang L, Zhou W, Velculescu VE, Kern SE, Hru-
mechanisms underlying the dedifferentiation pro- ban RH, Hamilton SR, Vogelstein B, Kinzler KW.
cess of isolated hepatocytes and their cultures. 1997. Gene expression profiles in normal and can-
Curr Drug Metab 7:629–660. cer cells. Science 276:1268–1272.
203. Nishimura M, Yokoi T, Tateno C, Kataoka M, 216. Marton MJ, DeRisi JL, Bennett HA, Iyer VR,
Takahashi E, Horie T, Yoshizato K, Naito S. Meyer MR, Roberts CJ, Stoughton R, Burchard
2005. Induction of human CYP1A2 and CYP3A4 J, Slade D, Dai H, Bassett DE Jr, Hartwell LH,
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
688 RUIZ-GARCIA ET AL.
Brown PO, Friend SH. 1998. Drug target valida- identified by gene expression profiling. Nature
tion and identification of secondary drug target 403:503–511.
effects using DNA microarrays. Nature medicine 225. Golub TR, Slonim DK, Tamayo P, Huard C, Gaa-
4:1293–1301. senbeek M, Mesirov JP, Coller H, Loh ML, Down-
217. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, ing JR, Caligiuri MA, Bloomfield CD, Lander ES.
Anders K, Eisen MB, Brown PO, Botstein D, 1999. Molecular classification of cancer: Class dis-
Futcher B. 1998. Comprehensive identification covery and class prediction by gene expression
of cell cycle-regulated genes of the yeast Sacchar- monitoring. Science 286:531–537.
omyces cerevisiae by microarray hybridization. 226. Perou CM, Sorlie T, Eisen MB, van de Rijn M,
Mol Biol Cell 9:3273–3297. Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen
218. Holstege FC, Jennings EG, Wyrick JJ, Lee TI, H, Akslen LA, Fluge O, Pergamenschikov A, Wil-
Hengartner CJ, Green MR, Golub TR, Lander liams C, Zhu SX, Lonning PE, Borresen-Dale AL,
ES, Young RA. 1998. Dissecting the regulatory Brown PO, Botstein D. 2000. Molecular portraits
circuitry of a eukaryotic genome. Cell 95:717–728. of human breast tumours. Nature 406:747–
219. Roberts CJ, Nelson B, Marton MJ, Stoughton R, 752.
Meyer MR, Bennett HA, He YD, Dai H, Walker 227. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M,
WL, Hughes TR, Tyers M, Boone C, Friend SH. Westermann F, Berthold F, Schwab M, Antonescu
2000. Signaling and circuitry of multiple MAPK CR, Peterson C, Meltzer PS. 2001. Classification
pathways revealed by a matrix of global gene and diagnostic prediction of cancers using gene
expression profiles. Science 287:873–880. expression profiling and artificial neural net-
220. Hughes TR, Marton MJ, Jones AR, Roberts CJ, works. Nature Med 7:673–679.
Stoughton R, Armour CD, Bennett HA, Coffey E, 228. van de Vijver MJ, He YD, van’t Veer LJ, Dai H,
Dai H, He YD, Kidd MJ, King AM, Meyer MR, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL,
Slade D, Lum PY, Stepaniants SB, Shoemaker Roberts C, Marton MJ, Parrish M, Atsma D, Wit-
DD, Gachotte D, Chakraburtty K, Simon J, Bard teveen A, Glas A, Delahaye L, van der Velde T,
M, Friend SH. 2000. Functional discovery via a Bartelink H, Rodenhuis S, Rutgers ET, Friend SH,
compendium of expression profiles. Cell 102:109– Bernards R. 2002. A gene-expression signature as
126. a predictor of survival in breast cancer. New Engl
221. Shoemaker DD, Schadt EE, Armour CD, He YD, J Med 347:1999–2009.
Garrett-Engele P, McDonagh PD, Loerch PM, 229. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla
Leonardson A, Lum PY, Cavet G, Wu LF, Altschu- LM, Angelo M, McLaughlin ME, Kim JY, Goum-
ler SJ, Edwards S, King J, Tsang JS, Schimmack nerova LC, Black PM, Lau C, Allen JC, Zagzag D,
G, Schelter JM, Koch J, Ziman M, Marton MJ, Li Olson JM, Curran T, Wetmore C, Biegel JA, Pog-
B, Cundiff P, Ward T, Castle J, Krolewski M, gio T, Mukherjee S, Rifkin R, Califano A, Stolo-
Meyer MR, Mao M, Burchard J, Kidd MJ, Dai vitzky G, Louis DN, Mesirov JP, Lander ES, Golub
H, Phillips JW, Linsley PS, Stoughton R, Scherer TR. 2002. Prediction of central nervous system
S, Boguski MS. 2001. Experimental annotation of embryonal tumour outcome based on gene expres-
the human genome using microarray technology. sion. Nature 415:436–442.
Nature 409:922–927. 230. Chang HY, Nuyten DS, Sneddon JB, Hastie T,
222. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Tibshirani R, Sorlie T, Dai H, He YD, van’t Veer
Ulrich RG. 2001. Microarray analysis of hepato- LJ, Bartelink H, van de Rijn M, Brown PO, van de
toxins in vitro reveals a correlation between gene Vijver MJ. 2005. Robustness, scalability, and inte-
expression profiles and mechanisms of toxicity. gration of a wound-response gene expression sig-
Toxicol Letters 120:359–368. nature in predicting breast cancer survival. Proc
223. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Natl Acad Sci U S A 102: 3738–3743.
Bennett L, Li L, Tennant R, Stoll R, Barrett JC, 231. Amundson SA, Bittner M, Meltzer P, Trent J,
Paules RS, Blanchard K, Afshari CA. 2002. Pre- Fornace AJ Jr. 2001. Induction of gene expression
diction of compound signature using high density as a monitor of exposure to ionizing radiation.
gene expression profiling. Toxicol Sci 67:232–240. Radiat Res 156:657–661.
224. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos 232. Curto EV, Lambert GW, Davis RL, Wilborn TW,
IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu Dooley TP. 2002. Biomarkers of human skin cells
X, Powell JI, Yang L, Marti GE, Moore T, Hudson identified using DermArray DNA arrays and new
J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, bioinformatics methods. Biochem Biophys Res
Chan WC, Greiner TC, Weisenburger DD, Armi- Commun 291:1052–1064.
tage JO, Warnke R, Levy R, Wilson W, Grever MR, 233. Mao M, Biery MC, Kobayashi SV, Ward T, Schim-
Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. mack G, Burchard J, Schelter JM, Dai H, He YD,
Distinct types of diffuse large B-cell lymphoma Linsley PS. 2004. T lymphocyte activation gene
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps
PHARMACOKINETICS IN DRUG DISCOVERY 689
identification by coregulated expression on DNA 247. Clark DE. 1999. Rapid calculation of polar
microarrays. Genomics 83:989–999. molecular surface area and its application to the
234. Sun L, Luo C, Long J, Wei D, Liu J. 2006. prediction of transport phenomena. 1. Prediction
Acrolein is a mitochondrial toxin: Effects on of intestinal absorption. J Pharm Sci 88:807–814.
respiratory function and enzyme activities in iso- 248. Smialowski P, Martin-Galiano AJ, Mikolajka A,
lated rat liver mitochondria. Mitochondrion 6: Girschick T, Holak TA, Frishman D. 2006. Protein
136–142. solubility: Sequence based prediction and experi-
235. Bajt ML, Cover C, Lemasters JJ, Jaeschke H. mental verification. Bioinformatics Dec. 6 [Epub
2006. Nuclear translocation of endonuclease g ahead of print].
and apoptosis-inducing factor during acetamino- 249. Sanchez-Castano G, Ruiz-Garcia A, Banon N,
phen-induced liver cell injury. Toxicol Sci 94:217– Bermejo M, Merino V, Freixas J, Garriguesx
225. TM, Pla-Delfina JM. 2000. Intrinsic absolute bioa-
236. Safiulina D, Peet N, Seppet E, Zharkovsky A, vailability prediction in rats based on in situ
Kaasik A. 2006. Dehydroepiandrosterone inhibits absorption rate constants and/or in vitro partition
complex I of the mitochondrial respiratory chain coefficients: 6-fluoroquinolones. J Pharm Sci 89:
and is neurotoxic in vitro and in vivo at high 1395–1403.
concentrations. Toxicol Sci 93:348–356. 250. Amidon GL, Sinko PJ, Fleisher D. 1988. Estimat-
237. Teng S, Ma L, Dong Y, Lin C, Ye J, Bahring R, ing human oral fraction dose absorbed: A correla-
Vardanyan V, Yang Y, Lin Z, Pongs O, Hui R. tion using rat intestinal membrane permeability
2004. Clinical and electrophysiological character- for passive and carrier-mediated compounds.
ization of a novel mutation R863X in HERG C- Pharm Res 5:651–654.
terminus associated with long QT syndrome. J Mol 251. Ekins S, Waller CL, Swaan PW, Cruciani G,
Med 82:189–196. Wrighton SA, Wikel JH. 2000. Progress in predict-
238. Scholz EP, Zitron E, Kiesecker C, Lueck S, Katho- ing human ADME parameters in silico.
fer S, Thomas D, Weretka S, Peth S, Kreye VA, J Pharmacol Toxicol Methods 44:251–272.
Schoels W, Katus HA, Kiehn J, Karle CA. 2003. 252. Balimane PV, Chong S. 2005. Cell culture-based
Drug binding to aromatic residues in the HERG models for intestinal permeability: A critique.
channel pore cavity as possible explanation for Drug Discov Today 10:335–343.
acquired Long QT syndrome by antiparkinsonian 253. Wei H, Lobenberg R. 2006. Biorelevant dissolution
drug budipine. Naunyn Schmiedebergs Arch media as a predictive tool for glyburide a class II
Pharmacol 368:404–414. drug. Eur J Pharm Sci 29:45–52.
239. Shioda T. 2004. Application of DNA microarray to 254. Sunesen VH, Pedersen BL, Kristensen HG, Mul-
toxicological research. J Environ Pathol Toxicol lertz A. 2005. In vivo in vitro correlations for a
Oncol 23:13–31. poorly soluble drug, danazol, using the flow-
240. Lettieri T. 2006. Recent applications of DNA through dissolution method with biorelevant dis-
microarray technology to toxicology and ecotoxi- solution media. Eur J Pharm Sci 24:305–313.
cology. Environ Health Perspect 114:4–9. 255. Parojcic J, Ethuric Z, Jovanovic M, Ibric S, Jova-
241. DiStefano JJ 3rd. 1982. Noncompartmental vs. novic D. 2004. Influence of dissolution media com-
compartmental analysis: Some bases for choice. position on drug release and in-vitro/in-vivo
Am J Physiol 243:R1–R6. correlation for paracetamol matrix tablets pre-
242. Nestorov I. 2003. Whole body pharmacokinetic pared with novel carbomer polymers. J Pharm
models. Clin Pharmacokinet 42:883–908. Pharmacol 56:735–741.
243. (CBER). USDoHaHSFaDACfDEaRCcfBEaR. 1999. 256. Artursson P. 1991. Cell cultures as models for drug
Guidance for industry. Population Pharmacokinet absorption across the intestinal mucosa. Crit Rev
244. Aarons L. 1991. Population pharmacokinetics: Ther Drug Carrier Syst 8:305–330.
Theory and practice. Br J Clin Pharmacol 32: 257. Rubas W, Cromwell ME, Shahrokh Z, Villagran J,
669–670. Nguyen TN, Wellton M, Nguyen TH, Mrsny RJ.
245. Bretschneider B, Brandsch M, Neubert R. 1999. 1996. Flux measurements across Caco-2 mono-
Intestinal transport of beta-lactam antibiotics: layers may predict transport in human large
Analysis of the affinity at the HR/peptide sympor- intestinal tissue. J Pharm Sci 85:165–169.
ter (PEPT1), the uptake into Caco-2 cell mono- 258. Artursson P, Palm K, Luthman K. 2001. Caco-2
layers and the transepithelial flux. Pharm Res monolayers in experimental and theoretical pre-
16:55–61. dictions of drug transport. Adv Drug Deliv Rev 46:
246. Camenisch G, Alsenz J, van de Waterbeemd H, 27–43.
Folkers G. 1998. Estimation of permeability by 259. Adachi Y, Suzuki H, Sugiyama Y. 2003. Quanti-
passive diffusion through Caco-2 cell monolayers tative evaluation of the function of small intestinal
using the drugs’ lipophilicity and molecular P-glycoprotein: Comparative studies between in
weight. Eur J Pharm Sci 6:317–324. situ and in vitro. Pharm Res 20:1163–1169.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008
690 RUIZ-GARCIA ET AL.
260. Tavelin S, Milovic V, Ocklind G, Olsson S, Arturs- mediated absorption from the gastrointestinal
son P. 1999. A conditionally immortalized epithe- tract. J Pharmacol Exp Ther 285:1175–1180.
lial cell line for studies of intestinal drug 270. Vrakas D, Giaginis C, Tsantili-Kakoulidou A.
transport. J Pharmacol Exp Ther 290:1212–1221. 2006. Different retention behavior of structurally
261. Tavelin S, Taipalensuu J, Hallbook F, Vellonen diverse basic and neutral drugs in immobilized
KS, Moore V, Artursson P. 2003. An improved cell artificial membrane and reversed-phase high per-
culture model based on 2/4/A1 cell monolayers formance liquid chromatography: Comparison
for studies of intestinal drug transport: Charac- with octanol-water partitioning. J Chromatogr A
terization of transport routes. Pharm Res 20:373– 1116:158–164.
381. 271. Buerger C, Plock N, Dehghanyar P, Joukhadar C,
262. Nagahara N, Tavelin S, Artursson P. 2004. Con- Kloft C. 2006. Pharmacokinetics of unbound line-
tribution of the paracellular route to the pH- zolid in plasma and tissue interstitium of critically
dependent epithelial permeability to cationic ill patients after multiple dosing using microdia-
drugs. J Pharm Sci 93:2972–2984. lysis. Antimicrob Agents Chemother 50:2455–
263. Gonzalez-Alvarez I, Fernandez-Teruel C, Garri- 2463.
gues TM, Casabo VG, Ruiz-Garcia A, Bermejo M. 272. Zhang L, Zhang Z, Wu K. 2006. In vivo and real
2005. Kinetic modelling of passive transport and time determination of ornidazole and tinidazole
active efflux of a fluoroquinolone across Caco-2 and pharmacokinetic study by capillary electro-
cells using a compartmental approach in NON- phoresis with microdialysis. J Pharm Biomed Anal
MEM. Xenobiotica 35:1067–1088. 41:1453–1457.
264. Ruiz-Garcia A, Lin H, Pla-Delfina JM, Hu M. 273. Amin RP, Vickers AE, Sistare F, Thompson KL,
2002. Kinetic characterization of secretory trans- Roman RJ, Lawton M, Kramer J, Hamadeh HK,
port of a new ciprofloxacin derivative (CNV97100) Collins J, Grissom S, Bennett L, Tucker CJ, Wild
across Caco-2 cell monolayers. J Pharm Sci 91: S, Kind C, Oreffo V, Davis JW 2nd, Curtiss S,
2511–2519. Naciff JM, Cunningham M, Tennant R, Stevens J,
265. Keely S, Rullay A, Wilson C, Carmichael A, Car- Car B, Bertram TA, Afshari CA. 2004. Identifica-
rington S, Corfield A, Haddleton DM, Brayden DJ. tion of putative gene based markers of renal
2005. In vitro and ex vivo intestinal tissue models toxicity. Environ Health Perspect 112:465–
to measure mucoadhesion of poly (methacrylate) 479.
and N-trimethylated chitosan polymers. Pharm 274. Thompson KL, Afshari CA, Amin RP, Bertram TA,
Res 22:38–49. Car B, Cunningham M, Kind C, Kramer JA, Law-
266. Pontier C, Pachot J, Botham R, Lenfant B, Arnaud ton M, Mirsky M, Naciff JM, Oreffo V, Pine PS,
P. 2001. HT29-MTX and Caco-2/TC7 monolayers Sistare FD. 2004. Identification of platform-inde-
as predictive models for human intestinal absorp- pendent gene expression markers of cisplatin
tion: Role of the mucus layer. J Pharm Sci 90: nephrotoxicity. Environ Health Perspect 112:
1608–1619. 488–494.
267. Ma TY, Hollander D, Bhalla D, Nguyen H, Kru- 275. Baker VA, Harries HM, Waring JF, Duggan CM,
gliak P. 1992. IEC-18, a nontransformed small Ni HA, Jolly RA, Yoon LW, De Souza AT, Schmid
intestinal cell line for studying epithelial perme- JE, Brown RH, Ulrich RG, Rockett JC. 2004.
ability. J Lab Clin Med 120:329–341. Clofibrate-induced gene expression changes in
268. Avdeef A, Tsinman O. 2006. PAMPA—a drug rat liver: A cross-laboratory analysis using mem-
absorption in vitro model 13. Chemical selectivity brane cDNA arrays. Environ Health Perspect
due to membrane hydrogen bonding: In combo 112:428–438.
comparisons of HDM-, DOPC-, and DS-PAMPA 276. Waring JF, Ulrich RG, Flint N, Morfitt D,
models. Eur J Pharm Sci 28:43–50. Kalkuhl A, Staedtler F, Lawton M, Beekman
269. Takagi M, Taki Y, Sakane T, Nadai T, Sezaki H, JM, Suter L. 2004. Interlaboratory evaluation of
Oku N, Yamashita S. 1998. A new interpretation rat hepatic gene expression changes induced by
of salicylic acid transport across the lipid bilayer: methapyrilene. Environ Health Perspect 112:439–
Implications of pH-dependent but not carrier- 448.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 97, NO. 2, FEBRUARY 2008 DOI 10.1002/jps